Inovio Pharmaceuticals, Inc.

Last price update: 27 Feb 24 23:00 GMT

Price:
$9.02
Open:
$8.38
Previous close:
$8.16
Day's range:
$8.32 - $9.08
Year's range:
$3.84 - $16.20
Net Income per Share:
-7.56
Price-to-Earnings ratio:
-1.19
52-week Price Range:
$6.84
Volume:
$685,293.00
Average volume:
$404,028.00

Company profile for Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

Stock exchanges:
NASDAQ
Sector:
Healthcare
Industries:
Biotechnology
Ticker:
INO
CIK:
0001055726
ISIN:
US45773H2013
Website:
https://www.inovio.com
Phone:
267 440 4200
Origin:
United States
Employees:
317

Inovio Pharmaceuticals, Inc. News

Buying Biotech Penny Stocks? 3 Things to Look For

Buying Biotech Penny Stocks? 3 Things to Look For

PennyStocks

Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript

Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript

Seeking Alpha

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Thomas Hong – Manager-Investor Communications Jacque Shea – President and Chief Executive Officer Michael Sumner – Chief Medical Officer Peter Kies – Chief Financial Officer Conference Call Participants Hartaj Singh – Oppenheimer & Company Operator Good day and welcome to the Inovio Third Quarter 2022 Results Conference Call. [Operator instructions] Please note that this event is being recorded.

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)

Inovio Pharmaceuticals, Inc. (INO) Presents at H.C. Wainwright 24th Annual Global Investment Conference (Transcript)

Seeking Alpha

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 24th Annual Global Investment Conference September 12, 2022 7:00 AM ET Company Participants Jacqueline Shea - President and CEO Conference Call Participants Brooke Katsof - H.C.

Inovio Pharmaceuticals, Inc. Press Releases

Inovio reports inducement grants under inducement plan

Plymouth meeting, pa. , feb. 3, 2023 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv associated diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 inducement plan ( the " inducement plan").

Inovio announces strategic reorganization, continues efforts to focus on promising dna medicine candidates

Cost saving measures include 11% headcount reduction annual savings expected to be approximately 4.3 million data readouts expected in first quarter of 2023 for key programs including ino 3107 for rrp and vgx 3100 for cervical hsil plymouth meeting, pa. , jan. 31, 2023 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from hpv associated diseases, cancer, and infectious diseases, today announced a strategic reorganization that is intended to deliver on commitments to operational efficiency and better position the company to bring the promise of dna medicines to PAT ients.

Inovio provides an update on lassa fever and mers programs

Plymouth meeting, pa. , nov. 17, 2022 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced that it has agreed with its collaborator, the coalition for epidemic preparedness innovations ( cepi), to discontinue development of product candidates targeting lassa fever ( ino 4500) and middle east respiratory SYN drome ( mers) ( ino 4700), following initial analyses of data from studies conducted by inovio and funded by cepi.

Inovio provides update on covid 19 heterologous booster vaccine candidate, ino 4800

Plymouth meeting, pa. , oct. 27, 2022 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced that it has discontinued its internally funded efforts to develop ino 4800 as a covid 19 heterologous booster vaccine.

Inovio reports positive interim phase 1 2 results for ino 3107 for the treatment of recurrent respiratory PAP illomatosis

Treatment with ino 3107 resulted in 16 of 21 (76%) participants with a reduction in number of surgical interventions compared with previous year; 6 participants required no surgical intervention during the trial ino 3107 demonstrated statistical significance based on CLI NIC al endpoint of reduction in overall number of surgical interventions compared with previous year ino 3107 was found to be well tolerated and immunogenic plymouth meeting, pa. , oct. 13, 2022 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and prevent infectious diseases, cancer, and diseases associated with hpv, today announced positive interim results from an ongoing phase 1 2 CLI NIC al trial evaluating ino 3107 for the treatment of hpv 6 and hpv 11 associated recurrent respiratory PAP illomatosis ( rrp) in adults.

Inovio reports inducement grants under inducement plan

Plymouth meeting, pa. , sept. 1, 2022 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help treat and protect people from infectious diseases, cancer, and diseases associated with hpv, today announced that it has made equity grants to two newly hired employees, including a vice president of CLI NIC al development, under its 2022 inducement plan ( the " inducement plan").

Inovio reports inducement grants under nasdaq listing rule 5635( c)(4)

Plymouth meeting, pa. , july 1, 2022 prnewswire inovio ( nasdaq ino), a biotechnology company focused on developing and commercializing dna medicines to help protect people from infectious diseases and treat people with cancer and hpv associated diseases, today announced that in connection with the hiring of dr. michael john sumner as chief medical officer, announced on june 27, 2022, the compensation committee of inovio' s board of directors approved equity grants to dr. sumner as inducement awards under inovio' s 2022 inducement plan ( the " inducement plan").

Inovio announces survival results for ino 5401 ino 9012 in combination with libtayo ( cemiplimab) in PAT ients with newly diagnosed gbm at asco annual meeting 2022

Inovio' s dna medicines immunotherapy in combination with libtayo elicits vaccine associated immune responses when administered with rt tmz to newly diagnosed gbm PAT ients ino 5401 ino 9012 libtayo elicits cancer antigen specific t cells 55% of mgmt methylated subjects remain alive at a median of 32.5 months dr. david reardon, principal investigator, to present on june 6, 2022 at asco plymouth meeting, pa. , may 27, 2022 prnewswire inovio ( nasdaq ino) announced results from the company' s novel phase 1 2 trial of ino 5401 and ino 9012 in combination with pd 1 inhibitor libtayo ( cemiplimab) in the treatment of newly diagnosed glioblastoma ( gbm), including encouraging median overall survival ( os) data from fifty two subjects.

Geneos therapeutics secures 17 million in series a2 financing to advance personalized cancer immunotherapy platform

Geneos expands its phase ib iia CLI NIC al trial in lead indication for treating PAT ients with advanced hepatocellular carcinoma financing led by flerie invest and dr. ted fjällman joins geneos' board of directors plymouth meeting, pa. , march 24, 2022 prnewswire geneos therapeutics, a CLI NIC al stage biotherapeutics company focused on the development of tumor neoantigen targeted personalized immunotherapies, announced today that it has secured 17 million in series a2 financing.

Inovio highlights key updates on phase 3 program for vgx 3100, its dna based immunotherapy for the treatment of cervical hsil caused by hpv 16 and or hpv 18

Plymouth meeting, pa., dec. 14, 2021 prnewswire inovio ( nasdaq ino), a biotechnology company focused on bringing to market precisely DES igned dna medicines to help protect people from infectious diseases and treat cancer and hpv associated diseases, today announced updates on the phase 3 program for vgx 3100 for hpv associated cervical high grade squamous intraepithelial lesions ( hsil), including a one year follow up of efficacy and safety data in participants from reveal1, completing enrollment in reveal2, and advancing its pre treatment biomarker candidate for vgx 3100 to be further developed with qiagen.